| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| None | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Claire’s Inc. (CLRS) | Credit Suisse/ J.P. Morgan/ Goldman Sachs | $100.00 | n.a. | |||
| n.a. (not available) | ||||||
| New Terms | ||||||
| AnaptysBio (ANAB) | Credit Suisse/ Stifel | 4.00 | $14.00 | $16.00 | $60.00 | S/O |
| Braeburn Pharmaceuticals (BBRX) | J.P. Morgan/ BofA Merrill Lynch | 7.69 | $18.00 | $21.00 | $150.00 | S/O |
| Jagged Peak Energy (JAG) | Citigroup/ Credit Suisse/ J.P. Morgan | 38.23 | $16.00 | $18.00 | $649.83 | S/O |
| JELD-WEN Holding (TBA) | Barclays/ Citigroup/ Credit Suisse/ J.P. Morgan | 25.00 | $21.00 | $23.00 | $550.00 | S/O |
| Jounce Therapeutics (JNCE) | J.P. Morgan/ Cowen and Company | 5.36 | $13.00 | $15.00 | $75.04 | S/O |
| Keane Group (FRAC) | Citigroup/ Morgan Stanley/ BofA Merrill Lynch/ J.P. Morgan | 22.30 | $17.00 | $19.00 | $401.40 | S/O |
| Laureate Education (LAUR) | Credit Suisse/ Morgan Stanley/ Barclays/ Macquarie Capital/ J.P. Morgan/ BMO Capital Markets/ Citigroup/ KKR/ Goldman Sachs | 29.00 | $17.00 | $20.00 | $536.50 | S/O |
| ObsEva SA (OBSV) | Credit Suisse/ Jefferies/ Leerink Partners | 6.45 | $14.00 | $16.00 | $96.75 | S/O |
| REV Group (REVG) | Goldman Sachs/ Morgan Stanley/ Baird | 12.50 | $19.00 | $21.00 | $250.00 | S/O |
| Visterra (VIST) | Leerink Partners/ Stifel | 3.85 | $12.00 | $14.00 | $50.05 | S/O |
| S/O (Subscribers Only) | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Jan. 16, 2017 | Manager(s) | Offered | Raised | Price | 1/20/17 | Change |
| Keane Group (FRAC) | Citigroup/ Morgan Stanley/ BofA Merrill Lynch/ J.P. Morgan | 26.76 | $508.44 | $19.00 | $21.65 | 13.95% |
| FinTech Acquisition Corp. II (FNTEU) (u) | Cantor Fitzgerald & Co. | 15.30 | $153.00 | $10.00 | $10.05 | 0.50% |
| u (unit offering) | ||||||
